Pfizer’s Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships
This article was originally published in The Pink Sheet Daily
Executive Summary
On the way back to his old job in the U.S., after a stint in Shanghai as head of research Asia, Richard Connell says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.
You may also be interested in...
Post-Lipitor Pfizer Will Have Two Business Models: Innovation And Value
Pfizer CEO Ian Read provided Wall Street with more clarity on his vision for the company as it moves beyond Lipitor into a new era. Pfizer will have two primary businesses, he said, an innovative pharmaceutical engine and a value business.
Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again
FDA’s Anti-Infective Drugs Advisory Committee will take its third look in less than four years at standards for developing antibacterial agents to treat community-acquired bacterial pneumonia, at a meeting on Nov. 3.
Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilars Rollout In India - BIO 2011 Conference
WASHINGTON - Pfizer Inc. is all set to kick-off its journey into the world of biosimilars as it gives finishing touches to the launch of a range of insulins in India. The company is counting on a set of value propositions, high quality and competitive pricing to emerge as a "natural leader" in the Indian market